Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with antibody-drug ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

The FDA is to probe safety concerns about cancer immunotherapies combinations in the light of signals from two trials involving Merck & Co’s Keytruda. The FDA has notified healthcare providers ...